Pregnancy Hypertension, 1(3-4), 262, 2011
O11. Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women
Author affiliations
- University of Messina ROR
Abstract not indexed. Read at publisher
Topics
myo-inositol PCOS pregnancy metabolic disorders prevention, inositol gestational diabetes PCOS prevention, PCOS pregnancy hypertensive disorders myo-inositol, D'Anna myo-inositol PCOS pregnant women, polycystic ovary syndrome pregnancy complications prevention, myo-inositol gestational hypertension PCOS, inositol metabolic syndrome pregnancy PCOS, PCOS antenatal supplementation myo-inositol, preeclampsia prevention PCOS insulin sensitizer
PMID 26009073 26009073 DOI 10.1016/j.preghy.2011.08.043 10.1016/j.preghy.2011.08.043
Cite this article
D'Anna, R., Benedetto, V., Rizzo, P., Raffone, E., Interdonato, M. L., Licata, G., Corrado, F., & Di Benedetto, A. (2011). O11. Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women. Pregnancy Hypertension, 1(3-4), 262. https://doi.org/10.1016/j.preghy.2011.08.043
D'Anna R, Benedetto V, Rizzo P, Raffone E, Interdonato ML, Licata G, et al. O11. Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women. Pregnancy Hypertens. 2011;1(3-4):262. doi:10.1016/j.preghy.2011.08.043
D'Anna, R., et al. "O11. Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women." Pregnancy Hypertension, vol. 1, no. 3-4, 2011, pp. 262.
Related articles
PregnancyHypertensive DisordersProgesterone SupplementationSystematic Review and Meta-Analysis
Open Access
Vaginal micronised progesterone for the prevention of hypertensive disorders of pregnancy: A systematic review and meta-analysis
Melo P et al., 2023·BJOG
Treatment with vaginal progesterone reduces the risk of miscarriage and preterm birth in selected high-risk women. The hypothesis that vaginal progesterone can reduce the risk of hypertensive disorders of pregnancy (HDP) is unexplored. To summarise the evidence on the effectiveness of vaginal progesterone to reduce the risk of HDP. We searched Embase (OVID), MEDLINE (OVID), PubMed, CENTRAL and clinicaltrials.gov from inception until 20 June 2023. We included placebo-controlled randomised trials (RCTs) of vaginal progesterone for the prevention or treatment of any pregnancy complications. We extracted absolute event numbers for HDP and pre-eclampsia in women receiving vaginal progesterone or placebo, and meta-analysed the data with a random effects model. We appraised the certainty of the evidence using GRADE methodology. The quantitative synthesis included 11 RCTs, of which three initiated vaginal progesterone in the first trimester, and eight in the second or third trimesters. Vaginal progesterone started in the first trimester of pregnancy lowered the risk of any HDP (risk ratio [RR] 0.71, 95% confidence interval [CI] 0.53-0.93, 2 RCTs, n = 4431 women, I(2) = 0%; moderate-certainty evidence) and pre-eclampsia (RR 0.61, 95% CI 0.41-0.92, 3 RCTs, n = 5267 women, I(2) = 0%; moderate-certainty evidence) when compared with placebo. Vaginal progesterone started in the second or third trimesters was not associated with a reduction in HDP (RR 1.19, 95% CI 0.67-2.12, 3 RCTs, n = 1602 women, I(2) = 9%; low-certainty evidence) or pre-eclampsia (RR 0.97, 95% CI 0.71-1.31, 5 RCTs, n = 4274 women, I(2) = 0%; low-certainty evidence). Our systematic review found first-trimester initiated vaginal micronised progesterone may reduce the risk of HDP and pre-eclampsia.
PCOSPregnancy-Induced HypertensionHypertensive DisordersGonadotropin Therapy
Polycystic ovary disease and the risk of pregnancy-induced hypertension
Kashyap S et al., 2001·J Reprod Med
To compare the incidence of pregnancy-induced hypertension in patients with and without polycystic ovary disease (PCOD). We conducted a retrospective, case-control analysis of patients who achieved singleton pregnancies with human menopausal gonadotropin (hMG) therapy. Twenty-two PCOD patients were compared to 27 infertility patients without PCOD who were pregnant after hMG therapy. Non-PCOD patients received hMG for superovulation as part of superovulation/intrauterine insemination or in vitro fertilization/embryo transfer. PCOD patients were receiving hMG for simple ovulation induction. Pregnancy-induced hypertension was defined as late pregnancy blood pressure > 140/90 mm Hg on two readings six hours apart and return to normal blood pressure by four to six weeks postpartum. There were no differences between PCOD and non-PCOD patients with reference to age, body mass index, parity or other pregnancy-induced hypertension risk factors (i.e., chronic hypertension, diabetes or chronic renal disease). Pregnant PCOD patients had a much higher incidence of pregnancy-induced hypertension, 31.8% (7/22), versus non-PCOD patients, who only had a pregnancy-induced hypertension incidence of 3.7% (1/27) (P = .016, OR = 12.1, 95% CI = 1.3-566.8). PCOD patients are at very high risk of pregnancy-induced hypertension when pregnant after ovulation induction.
PregnancyHypertensive DisordersDonor Gamete OutcomesImmunological Factors in Preeclampsia
The influence of donated gametes on the incidence of hypertensive disorders of pregnancy
Salha O et al., 1999·Hum Reprod
Pregnancies achieved from oocyte, sperm or embryo donation are unique, since they have resulted from donor gametes that are immunologically foreign to the mother. Thus, studying the obstetric outcome of such pregnancies may shed some light on the pathophysiology of preeclampsia, particularly in women conceiving with donated embryos, since the entire fetal genome is allogenic in these pregnancies. In this retrospective cohort study, a total of 144 women were studied. Of these, 72 were infertility patients who had conceived as a result of sperm, ovum or embryo donation and the other 72 women were age- and parity-matched control patients who became pregnant with their own gametes, either spontaneously, or following intrauterine insemination with their partner's spermatozoa. Study patients were divided into three groups depending on the origin of the donated gametes. Group 1 consisted of pregnancies achieved by intrauterine insemination with washed donor spermatozoa (n = 33). Group 2 included women who conceived using donated oocytes (n = 27) and group 3 consisted of women who conceived as a result of embryo donation (n = 12). The incidence of pregnancy-induced hypertension in the donated gametes study group was 12.5% (9/72) compared with 2.8% (2/72) in the control group. In addition, pre-eclampsia was diagnosed in 18.1% (13/72) of the donated gametes study group compared to 1.4% (1/72) in the age- and parity-matched controls. The increased incidence of gestational hypertension in pregnancies resulting from donated gametes gives evidence for a maternal genetic component, with an equally strong fetal influence, in the complicated aetiology of gestational hypertension, and pre-eclampsia in particular.